Author | David Ross Camidge, MD, PhD | OncLive

Author | David Ross Camidge, MD, PhD

Articles

Dr. Camidge on Biomarker Combinations in NSCLC

August 10, 2018

Video

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).

Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC

June 29, 2018

Video

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses the updated efficacy and safety data from the global phase III ALEX study of alectinib (Alecensa) versus crizotinib (Xalkori) in untreated advanced ALK-positive non–small cell lung cancer (NSCLC).

x